The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
Autor: | Manjit Matharu, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Sheena K. Aurora |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: | |
Zdroj: | The Journal of Headache and Pain, Vol 18, Iss 1, Pp 1-8 (2017) |
Druh dokumentu: | article |
ISSN: | 1129-2369 1129-2377 |
DOI: | 10.1186/s10194-017-0784-4 |
Popis: | Abstract Background OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. Methods Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a 24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week, 3-treatment cycle, open-label phase) were pooled for analysis. Patients kept a daily diary to record headache severity on a 4-point scale (from none to severe), and a 6-domain Headache Impact Test (HIT-6) was used to determine the clinical impact of headaches. Analysis was undertaken to assess whether the subset of patients that were headache-day frequency non-responders at week 24 (patients with |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |